You are in: eMedicine Specialties > Emergency Medicine > Toxicology
|
Toxicity, Phencyclidine Last Updated: March 20, 2006 |
|
| Synonyms and related keywords: phencyclidine toxicity, PCP, angel dust, peace pill, crystal joint, hog, supergrass, wack , rocket fuel, KJ, illy, elephant tranquilizer, wet, hydro, fry
|
|   |
AUTHOR INFORMATION
| Section 1 of 10  |
|
| Author: Nicole S Johnson, MD, Staff Physician, Department of Emergency Medicine, State University of New York Downstate Medical Center, Kings County Hospital Coauthor(s): Mark A Silverberg, MD, FACEP, MMB, Assistant Professor of Emergency Medicine, State University of New York Downstate College of Medicine, Assistant Residency Director, Department of Emergency Medicine, Kings County Hospital |
| Nicole S Johnson, MD, is a member of the following medical societies:
American College of Emergency Physicians,
Emergency Medicine Residents' Association,
National Medical Association, and
Society for Academic Emergency Medicine |
| Editor(s): Lance W Kreplick, MD, MMM, Medical Director, Department of Emergency Medicine, Regional Medical Center - Bayonet Point; John T VanDeVoort, PharmD, Clinical Assistant Professor, College of Pharmacy, University of Minnesota;
Fred Harchelroad, MD, FACMT, Chair, Department of Emergency Medicine, Director of Medical Toxicology, Associate Professor, Department of Emergency Medicine, Allegheny General Hospital;
John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School;
and Asim Tarabar, MD, Assistant Clinical Professor of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital |
Disclosure
|   |
INTRODUCTION
| Section 2 of 10  |
|
Background: Phencyclidine (PCP) was originally developed for use as a general anesthetic for surgery under the trade name Sernyl in the 1950s. Its use was discontinued in humans in 1965 because it often produced postanesthetic delirium with psychotic features, dysphoria, and occasionally extreme agitation. PCP under the name Sernylan was used as a veterinary anesthetic until 1978, after which time it became illegal to use altogether.
In the 1960s, people began manufacturing phencyclidine in laboratories illegally, and, by the late 1970s, it became a popular street drug. Common street names include angel dust, peace pill, crystal joint, hog, rocket fuel, KJ, elephant tranquilizer, supergrass, and wack. PCP is a white crystalline powder that is available in liquid, tablet, or powder forms. It can be snorted, ingested orally, or injected intravenously. It also can be smoked as a "joint" when sprinkled on cigarettes or applied to mint or marijuana leaves. PCP is often taken in conjunction with other co-ingestants, including ethanol and marijuana.
Pathophysiology: PCP, also known as 1-(1-phenylcyclohexyl-piperidine), is classified as a dissociative anesthetic. PCP acts mainly in the CNS, producing both stimulation and depression. Its sympathomimetic effects are thought to be due to weak reuptake inhibition of norepinephrine and dopamine. PCP also exerts some cholinergic and anticholinergic effects and has some other actions at nicotinic and opioid receptors.
The dissociative properties of PCP are believed to be due to its actions as a glutamate antagonist at the N-methyl-D-aspartate (NMDA) receptors. NMDA antagonists have been known to produce behavioral effects similar to those observed in schizophrenia. PCP also affects the actions of dopamine, which may cause the psychomotor effects seen with PCP.
Clinical effects occur within minutes and usually last several hours. These symptoms may last up to 48 hours in the event of significant overdose. However, even more prolonged effects may be seen in chronic users either from enterohepatic recirculation or delayed release of PCP from lipid stores. PCP is primarily metabolized in the liver. Frequency:
- In the US: In a 2004 survey of US high school seniors, 1.6% of students reported ever using PCP in their lifetime, 0.7% reported using it at least once in the last year, and 0.4% reported using it at least once in the last 30 days.
Mortality/Morbidity: Doses of 20 mg or more may cause prolonged coma, seizures, and even death. One death has been reported from an ingestion of 150-200 mg in an acute overdose. The American Association of Poison Control Centers reported 6 deaths from PCP in 2002. Morbidity and mortality are usually associated with rhabdomyolysis, renal failure, hypertensive crises, accidental trauma, and self-destructive behavior.
Race: According to the Drug Abuse Warning Network (DAWN) report of 2004, of all PCP-related ED visits in 2002, 43% of abusers were black, 30% were white, and 12% were Hispanic.
Sex: Nationally, patients presenting to the ED for PCP are more likely to be male (64%) than female (36%).
Age: According to a national survey in 2003, 3% of the population aged 12 years and older reported using PCP at least once. In the DAWN report of 2004, patients aged 18-25 years accounted for 38% of PCP-related ED visits in 2002.
|   |
CLINICAL
| Section 3 of 10  |
|
History: Because of the numerous routes of administration, variations in dosage, and possibility of co-ingestants, PCP produces a wide variety of physical and behavioral effects. Most commonly, witnesses may report agitation, bizarre actions, or violent behavior. Users of PCP often appear to be having a psychotic episode and may or may not report to the physician that they have taken the drug. Physical: Based on a study by McCarron et al in which 1,000 patients presenting with acute phencyclidine intoxication were evaluated, clinical effects ranged from lethargy and coma to extreme agitation and psychosis.
Common physical examination findings include the following: - Nystagmus (horizontal, vertical, or rotary) - Often considered a hallmark of PCP intoxication (57-89%)
- Acute brain syndrome involving confusion, amnesia, disorientation, and violence (37%)
- Agitation and violent behavior (35%)
- Bizarre behavior including public nudity (29%)
- Hallucinations and delusions (19%)
- Miosis - Often reported with a blank stare
- Rare findings - Usually only seen with high doses
- Apnea (often seen with co-ingestants)
- Coma - PCP coma usually presents with nystagmus and the absence of respiratory depression. Unlike opioid-induced coma, it does not improve with naloxone.
- Intracranial and subarachnoid hemorrhage
- Other manifestations include the following:
- Hyperthermia, hyperreflexia, and muscle rigidity have been reported.
- Rhabdomyolysis with or without acute renal failure may also occur.
|   |
DIFFERENTIALS
| Section 4 of 10  |
|
Alcohol and Substance Abuse Evaluation Anxiety Delirium Tremens Depression and Suicide Encephalitis Epidural Hematoma Epidural and Subdural Infections Herpes Simplex Herpes Simplex Encephalitis
Hypertensive Emergencies Hyperventilation Syndrome Hypoglycemia Hyponatremia Meningitis Neoplasms, Brain Neuroleptic Malignant Syndrome Panic Disorders Personality Disorders
Plant Poisoning, Herbs Plant Poisoning, Hypoglycemics Schizophrenia Toxicity, Cocaine Toxicity, Hallucinogen Toxicity, MDMA Toxicity, Medication-Induced Dystonic Reactions Toxicity, Methamphetamine Toxicity, Mushroom - Hallucinogens
Toxicity, Selective Serotonin Reuptake Inhibitor Toxicity, Sympathomimetic Withdrawal Syndromes
Other Problems to be Considered:
Lysergic acid diethylamide toxicity
Plant poisoning, mescaline
Malignant hyperthermia
Serotonin syndrome |
| Related Articles | Alcohol and Substance Abuse Evaluation
Anxiety
Delirium Tremens
Depression and Suicide
Encephalitis
Epidural Hematoma
Epidural and Subdural Infections
Herpes Simplex
Herpes Simplex Encephalitis
Hypertensive Emergencies
Hyperventilation Syndrome
Hypoglycemia
Hyponatremia
Meningitis
Neoplasms, Brain
Neuroleptic Malignant Syndrome
Panic Disorders
Personality Disorders
Plant Poisoning, Herbs
Plant Poisoning, Hypoglycemics
Schizophrenia
Toxicity, Cocaine
Toxicity, Hallucinogen
Toxicity, MDMA
Toxicity, Medication-Induced Dystonic Reactions
Toxicity, Methamphetamine
Toxicity, Mushroom - Hallucinogens
Toxicity, Selective Serotonin Reuptake Inhibitor
Toxicity, Sympathomimetic
Withdrawal Syndromes
|
|
|
|
|
|   |
WORKUP
| Section 5 of 10  |
|
Lab Studies:
- The diagnosis of PCP intoxication is a difficult one to make without some sort of history of drug use from the patient. It should be considered in patients with bizarre behavior, hypertension, and nystagmus, or coma unresponsive to naloxone in a substance abuser. One of the very typical scenarios involves a nude patient walking on the street or between moving vehicles.
- Exposure to PCP can be confirmed by qualitative urine toxicology screening. Serum screening for PCP is not useful clinically because the test is not readily available. In addition, quantitative serum PCP level does not correlate with the symptoms.
- A fingerstick should be performed in all patients with altered mental status. McCarron et al found that 20% of patients with acute PCP intoxication were hypoglycemic.
- No laboratory tests are specific for PCP intoxication, but, in addition to hypoglycemia, elevations in WBC count and BUN and creatinine levels may be seen.
- Serum creatine phosphokinase and urine myoglobin levels should also be measured to rule out rhabdomyolysis, especially in the patients with severe agitation.
- Consider an arterial blood gas (ABG) to assess for hypoxemia and metabolic acidosis in unresponsive patients.
- Urine pregnancy tests are indicated for female patients of childbearing age.
Imaging Studies:
- No imaging studies are necessary for the evaluation of acute PCP intoxication.
- Consider a CT scan of the head to rule out an intracranial cause for altered mental status.
- Consider specific imaging to evaluate traumatic injuries associated with PCP intoxication.
Procedures:
- For patients who are unable to protect their airway or have evidence of respiratory compromise, endotracheal intubation and mechanical ventilation may be needed.
- Consider lumbar puncture in patients with altered mental status and fever in whom the diagnosis is unclear.
|   |
TREATMENT
| Section 6 of 10  |
|
Prehospital Care: - Evaluate and stabilize the patient's airway, breathing, and circulation (ABCs) including cervical spine immobilization if traumatic injury is suspected.
- Physical restraints may be required to prevent self-injury and to protect the medical staff. These patients should be monitored closely due to several death reports of PCP-intoxicated patients while being physically restrained.
- Chemical restraints may also be used. Establish intravenous access and administer benzodiazepines for cases of severe agitation. Intramuscular benzodiazepines are an alternative if intravenous access is unobtainable.
Emergency Department Care: - After addressing and stabilizing the ABCs, treatment of PCP intoxication starts with initial supportive measures (IV, O2, cardiac monitor). ECG may be indicated to assess for dysrhythmias.
- Obtain a fingerstick to rule out hypoglycemia.
- Place patients in a dark, quiet room under continuous observation to minimize environmental stimuli.
- Consider activated charcoal for oral ingestions and co-ingestions. Multiple doses of charcoal may be beneficial in the case of large overdose. Only one dose of sorbitol should be given, usually with the initial dose.
- Extreme violent psychotic behavior requires sedation with parenteral benzodiazepines. Seizures should be treated with benzodiazepines. Butyrophenones and phenothiazines should be avoided in moderate and severe intoxications because they can lower seizure threshold, cause dystonic reactions and hypotension, and worsen anticholinergic symptoms, including hyperthermia. Haldol should be reserved for the patients with mild, predominately psychotic symptoms, with normal vital signs.
- Patients with respiratory insufficiency or failure may require endotracheal intubation.
- Hyperthermia may be treated by conventional cooling methods.
- Rhabdomyolysis is treated with intravenous hydration and urine alkalinization. Possible caveat: a theoretical, but clinically unproven, concept of increase PCP reabsorption secondary to the urine alkalinization.
- For hypertensive emergencies, try to control agitation first with parenteral benzodiazepines. For persistent hypertension, intravenous nitroprusside is the agent of choice. Because of the theoretical concept of unopposed alpha effect (worsening of hypertension) and the availability of other antihypertensive agents (eg, calcium-channel blockers, intravenous nitroglycerin), pure beta-blockade should be avoided. Labetalol, however, which has both alpha and beta blockade, may be beneficial.
- New research is centered about the development of antibodies to neutralize the toxic effects of PCP.
- Acute PCP toxicity can usually be managed conservatively with an observation period of a few hours. More serious ingestions may require admission to an intensive care unit for days to weeks.
Consultations: Consult with a board-certified medical toxicologist or a local poison control center for further recommendations.
|   |
MEDICATION
| Section 7 of 10  |
|
Drug Category: Benzodiazepines -- Indications include agitation, violent behavior, psychosis, seizures, and muscular rigidity. Drug Name
| Diazepam (Valium) -- Enhances GABA transmission. Appears to act on part of the limbic system, the thalamus and hypothalamus, to induce a calming effect. Rapidly distributes to other body fat stores. Twenty minutes after initial IV infusion, serum concentration drops to 20% of Cmax.
Individualize dosage and increase cautiously to avoid adverse effects.| Adult Dose | 5-10 mg IV; repeat q5-10min prn; IM/PR may be used if IV not available |
|---|
| Pediatric Dose | 30 days to 5 years: 0.2-0.5 mg IV (slowly) q2-5min prn; not to exceed 5 mg
>5 years: 1 mg IV (slowly) q2-5min prn; not to exceed 10 mg| Contraindications | Documented hypersensitivity; narrow-angle glaucoma |
|---|
| Interactions | Phenothiazines, barbiturates, alcohols, and MAO inhibitors increase CNS toxicity when administered concurrently |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Caution with other CNS depressants, low albumin levels, or hepatic disease (may increase toxicity); monitor for respiratory depression with high or repeated doses |
|---|
|
|---|
| Drug Name
| Lorazepam (Ativan) -- Short-acting anxiolytic with relatively long half-life.
Increases transmission of GABA, a major inhibitory neurotransmitter in the brain.
May be used IV and is well-absorbed after IM injection. Onset of action occurs within min of an injection, and effects peak 15-20 min after injection. Duration of action is 6-8 h. No active metabolites exist.| Adult Dose | 1-4 mg IV/IM; may repeat q15min prn; not to exceed 8 mg
Status epilepticus: 0.05-0.1 mg/kg IV over 2-5 min; may repeat in 10-15 min prn; not to exceed 8 mg/dose| Pediatric Dose | 0.05-0.1 mg/kg IV slowly over 2-5 min, maximum 4 mg/dose |
|---|
| Contraindications | Documented hypersensitivity; preexisting CNS depression; hypotension; narrow-angle glaucoma |
|---|
| Interactions | Toxicity of benzodiazepines in CNS increases when used concurrently with alcohol, phenothiazines, barbiturates, and MAO inhibitors |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Caution in renal or hepatic impairment, myasthenia gravis, organic brain syndrome, or Parkinson disease; monitor for respiratory depression with high or repeated doses |
|---|
|
|---|
|
|---|
Drug Name
| Midazolam (Versed) -- Used as alternative in termination of refractory status epilepticus. Because water soluble, takes approximately 3 times longer than diazepam to peak EEG effects. Thus, clinician must wait 2 min to fully evaluate sedative effects before initiating procedure or repeating dose. Has twice the affinity for benzodiazepine receptors than diazepam. May be administered IM if unable to obtain vascular access. |
|---|
| Adult Dose | 0.01-0.05 mg/kg (usually 0.5-4 mg, not to exceed 10 mg) IV slowly over several min; may repeat q10-15min prn |
|---|
| Pediatric Dose | <32 weeks: 0.5 mcg/kg/min IV infusion
>32 weeks: 1 mcg/kg/min IV infusion
Children: 0.05-0.2 mg/kg IV over 2-3 min, followed by 1-2 mcg/kg/min continuous infusion
Status epilepticus (refractory to standard therapy), >2 months and children: 0.15 mg/kg followed by continuous infusion of 1 mcg/kg/min, titrate upward q5min prn| Contraindications | Documented hypersensitivity; preexisting hypotension; narrow-angle glaucoma |
|---|
| Interactions | Sedative effects of midazolam may be antagonized by theophyllines; narcotics and erythromycin may accentuate sedative effects of midazolam due to decreased clearance |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure; monitor for respiratory depression with high or repeated doses |
|---|
|
|---|
Drug Category: Neuroleptics -- These agents are used for acute psychosis when no contraindications are present.Drug Name
| Haloperidol (Haldol) -- Butyrophenone noted for high potency and low potential for causing orthostasis. Downside is high potential for EPS and dystonia. Lowers seizure threshold and worsens anticholinergic symptoms, including hyperthermia. Should be reserved only for mild PCP intoxications with predominantly psychotic features and normal vital signs.
Parenteral dosage form may be admixed with 2 mg lorazepam for better anxiolytic effects.| Adult Dose | 0.5-5 mg IV (unlabeled use), may be repeated q30min
2-5 mg IM q1-8h; not to exceed 100 mg/d| Pediatric Dose | <3 years: Not established
3-12 years: 0.5 mg IV/IM
>12 years: Administer as in adults| Contraindications | Documented hypersensitivity; narrow-angle glaucoma; bone marrow suppression; severe cardiac or liver disease; severe hypotension; hyperthermia; seizures |
|---|
| Interactions | May increase tricyclic antidepressant serum concentrations and hypotensive action of antihypertensive agents; phenobarbital or carbamazepine may decrease effects of haloperidol; haloperidol coadministration with anticholinergics may increase intraocular pressure; encephalopathylike syndrome associated with concurrent administration of lithium and haloperidol |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Severe neurotoxicity manifesting as rigidity or inability to walk or talk may occur in patients with thyrotoxicosis also receiving antipsychotics; if IV/IM, watch for hypotension; caution in those with CNS depression, subcortical brain damage, or cardiac disease; if history of seizures, benefits must outweigh risks; significant increase in body temperature may indicate intolerance to antipsychotics (discontinue if this occurs) |
|---|
|
|---|
|
|---|
|
|---|
Drug Category: Antihypertensives -- These agents are used for blood pressure control in hypertensive crises to minimize end-organ damage.Drug Name
| Nitroprusside -- Produces vasodilation and increases inotropic activity of the heart. At higher dosages, may exacerbate myocardial ischemia by increasing the heart rate. |
|---|
| Adult Dose | Begin infusion at 0.3-0.5 mcg/kg/min IV and use increments of 0.5 mcg/kg/min; titrate to desired effect; average dose is 1-6 mcg/kg/min
Infusion rates >10 mcg/kg/min may lead to cyanide toxicity| Pediatric Dose | Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity; subaortic stenosis; decreased cerebral perfusion; arteriovenous shunt or coarctation of aorta (eg, compensatory hypertension); atrial fibrillation or flutter |
|---|
| Interactions | Effects are additive when administered with other hypotensive agents |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Caution in increased intracranial pressure, hepatic failure, severe renal impairment, and hypothyroidism; in renal or hepatic insufficiency, nitroprusside levels may increase and can cause cyanide toxicity at high infusion rates and when used in combination with a diuretic; sodium nitroprusside has ability to lower blood pressure and thus should be used only in patients with mean arterial pressures >70 mm Hg |
|---|
|
|---|
Drug Category: GI decontaminant -- These agents prevent further absorption of adsorbable toxins from the GI tract. They are most beneficial if administered within 1-2 h of ingestion.Drug Name
| Activated charcoal (Liqui-Char) -- Because PCP undergoes enterohepatic recirculation, may be indicted if clinically feasible. Emergency treatment in poisoning caused by drugs and chemicals. Network of pores present in activated charcoal adsorbs 100-1000 mg of drug per gram of charcoal. Does not dissolve in water. |
|---|
| Adult Dose | 1 g/kg PO/NG (30-100 g usual dose) typically as a mixture with 70% sorbitol or similar cathartic; may administer 0.5 g/kg PO/NG as repeat dose if desired |
|---|
| Pediatric Dose | <2 years: 1 g/kg PO/NG (15-30 g usual dose); may administer 0.5 g/kg PO/NG as repeat dose prn; coadministration with cathartic not recommended
>2 years: Administer as in adults| Contraindications | Documented hypersensitivity; poisoning or overdose of mineral acids and alkalies; unprotected airway with absent gag reflex |
|---|
| Interactions | May inactivate syrup of ipecac if used concomitantly; effectiveness of other medications decrease with coadministration; do not mix charcoal with sherbet, milk, or ice cream (decreases absorptive properties of activated charcoal) |
|---|
| Precautions | Protect airway to reduce risk of aspiration; not very effective in poisonings of ethanol, methanol, and iron salts; induce emesis before administration; after emesis with ipecac, patient may not tolerate activated charcoal for 1-2 h; can administer in early stages of gastric lavage; without sorbitol, gastric lavage returns are black; if comatose, administer via nasogastric tube |
|---|
|
|---|
|   |
FOLLOW-UP
| Section 8 of 10  |
|
Further Inpatient Care:
- Any patient with evidence of unrelenting agitation, hypertensive crisis, hyperthermia, seizures, respiratory depression, rhabdomyolysis, or severe traumatic injuries should be admitted to the hospital, and possibly to an intensive care setting if indicated.
- Consider a psychiatric evaluation for substance abuse counseling and/or suicidal ideations.
Further Outpatient Care:
- Consider referral to a drug rehabilitation program. Repeated use of PCP can result in addiction, and abrupt discontinuation of the drug can produce withdrawal symptoms including craving, confusion, and depression.
Complications:
- Chronic PCP toxicity results in cognitive deficits and mood disorders. Patients can develop speech impediments and also suffer from dysphoria, depression, anxiety, and psychosis.
- Occult traumatic injuries must be ruled out. Perform a thorough physical examination on all patients under the influence of PCP.
Prognosis:
- Patients who present with rhabdomyolysis, renal failure, seizures, hyperthermia, hypertensive crises, and traumatic injuries tend to have worse outcomes.
Patient Education:
|   |
MISCELLANEOUS
| Section 9 of 10  |
|
Medical/Legal Pitfalls:
- The acute toxicity of PCP is often misdiagnosed because of its similarity to schizophrenic episodes. In fact, PCP-induced psychosis may respond to antipsychotics, which may further confound the diagnosis.
- Do not rely on the urine toxicology screen to diagnose acute PCP intoxication. Chronic PCP users can have positive test results for weeks after their last use. Cases of false-positive results for PCP have also been reported with diphenhydramine (Benadryl) and dextromethorphan, an agent in over-the-counter cough formulations that can produce clinical effects similar to PCP when taken in high doses.
- Failure to diagnose or address hypoglycemia, hyperthermia, traumatic injuries, or rhabdomyolysis is medical malpractice.
|   |
BIBLIOGRAPHY
| Section 10 of 10 |
|
-
Babu K, Boyer E, et al: Emerging Drugs of Abuse. Clinical Pediatric Emergency Medicine 2005 Jun; 6(2): 81-4.
-
Bryson P: Phencyclidine. In: Comprehensive Review in Toxicology for Emergency Clinicians. 3rd ed. Taylor & Francis; 1996: 509-16.
-
Drug Abuse Warning Network: Trends in PCP-Related Emergency Department Visits. The Drug Abuse Warning Network Report 2004 Jan;[Full Text].
-
Goldfrank LR, et al: Phencyclidine and Ketamine. In: Goldfrank's Toxicologic Emergencies. 7th ed. New York: McGraw-Hill; 2002: chap 69.
-
Greydanus DE, Patel DR: Substance abuse in adolescents: a complex conundrum for the clinician. Pediatr Clin North Am 2003 Oct; 50(5): 1179-223[Medline].
-
Haroz R, Greenberg MI: Emerging drugs of abuse. Med Clin North Am 2005 Nov; 89(6): 1259-76[Medline].
-
Leshner A: Hallucinogens and Dissociative Drugs Including LSD, PCP, Ketamine, Dextromethorphan. National Institute on Drug Abuse Research Report Series 2001 Mar; NIH Pub. No. 01-4209.
-
Marx JA, Hockberger RS, Walls RM: Phencyclidine. In: Rosen's Emergency Medicine Concepts and Clinical Practice. 5th ed. St Louis: Mosby Inc; 2002: 2146-8.
-
McCarron MM, Schulze BW, Thompson GA, et al: Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med 1981 Jun; 10(6): 290-7[Medline].
-
Mokhlesi B, Leikin JB, Murray P, Corbridge TC: Adult toxicology in critical care: Part II: specific poisonings. Chest 2003 Mar; 123(3): 897-922[Medline].
-
National Institute on Drug Abuse: 2004 Monitoring the Future (MTF) Survey, funded by the National Institute on Drug Abuse, National Institutes of Health, DHHS, and conducted by the University of Michigan's Institute for Social Research. [Full Text].
-
OAS Home of Alcohol, Tobacco, and Drug Abuse Statistics: 2003 National Survey on Drug Use and Health (NSDUH). [Full Text].
-
Poisindex Editorial Staff: Phencyclidine (Acute Toxicity). In: Klasco RK, ed. POISINDEX System. Thomson Micromedex, Greenwood Village, CO; 2005.
-
Rimsza ME, Moses KS: Substance abuse on the college campus. Pediatr Clin North Am 2005 Feb; 52(1): 307-19[Medline].
-
Wills B, Erickson T: Drug- and toxin-associated seizures. Med Clin North Am 2005 Nov; 89(6): 1297-321[Medline].
Toxicity, Phencyclidine excerpt |